Evidence map›Paper›PMID 40144796›Full record

ArticleBioactive materials2025

Silicified curcumin microspheres Combats cardiovascular diseases via Nrf2/HO-1 pathway.

Tianwang Guan, Zhenxing Lu, Rundong Tai, Shuai Guo, Zhaowenbin Zhang, Shaohui Deng, Jujian Ye, Kaiyi Chi, Binghua Zhang, Huiwan Chen and 6 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Bioactive materials, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Tianwang GuanGuangdong Engineering Research Center of Boron Neutron Therapy and Application in Malignant Tumors, Dongguan Key Laboratory of Precision Diagnosis and Treatment for Tumors, Dongguan Engineering Research Center for Innovative Boron Drugs and Novel Radioimmune Drugs, Cancer Center, The 10th Affiliated Hospital of Southern Medical University (Dongguan People's Hospital), Southern Medical University, Guangdong, 523059, China.
Zhenxing LuGuangdong Provincial Key Laboratory of Cardiac Function and Microcirculation, Guangzhou, 510280, China.
Rundong TaiGuangdong Provincial Key Laboratory of Cardiac Function and Microcirculation, Guangzhou, 510280, China.
Shuai GuoThe Tenth Affiliated Hospital (Dongguan People's Hospital), Southern Medical University, Dongguan, 523059, China.
Zhaowenbin ZhangCollege of Biological Science and Medical Engineering, Donghua University, Shanghai, 201620, China.
Shaohui DengThe Tenth Affiliated Hospital (Dongguan People's Hospital), Southern Medical University, Dongguan, 523059, China.
Jujian YeGuangdong Provincial Key Laboratory of Cardiac Function and Microcirculation, Guangzhou, 510280, China.
Kaiyi ChiGuangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, 510182, China.
Binghua ZhangDepartment of Clinical Medicine, Clinical Medical School, Guangzhou Medical University, Guangzhou, 510180, China.
Huiwan ChenGuangdong Provincial Key Laboratory of Cardiac Function and Microcirculation, Guangzhou, 510280, China.
Zhilin DengThe Tenth Affiliated Hospital (Dongguan People's Hospital), Southern Medical University, Dongguan, 523059, China.
Yushen KeGuangdong Provincial Key Laboratory of Cardiac Function and Microcirculation, Guangzhou, 510280, China.
Andong HuangDepartment of Clinical Medicine, Clinical Medical School, Guangzhou Medical University, Guangzhou, 510180, China.
Peier ChenGuangdong Provincial Key Laboratory of Cardiac Function and Microcirculation, Guangzhou, 510280, China.
Chunming WangState Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Taipa, Macau SAR, 999078, China.
Caiwen OuGuangdong Provincial Key Laboratory of Cardiac Function and Microcirculation, Guangzhou, 510280, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Diabetes and chemotherapy frequently give rise to severe cardiovascular complications, including chemotherapy-induced cardiotoxicity and diabetes-associated vascular remodeling. Nevertheless, the precise epidemiological features of these cardiovascular ailments remain incompletely elucidated, resulting in a dearth of effective therapeutic strategies in clinical settings. To tackle this intricate challenge, we have delved extensively into database resources, conducted comprehensive analyses of pertinent epidemiological data, and designed silicified curcumin (Si/Cur) microspheres as a novel therapeutic approach for cardiovascular diseases. By harnessing the alkaline microenvironment generated by silicon (Si), Si/Cur markedly elevates the bioavailability of curcumin (Cur). Further investigations have elucidated that Si/Cur exerts its therapeutic actions primarily via the Nrf2/HO-1 signaling pathway, effectively suppressing vascular remodeling and mitigating myocardial injury, thus disrupting the vicious cycle of persistent cardiovascular damage. In conclusion, this study integrates clinical cohort research to dissect epidemiological characteristics, directs the design and application of biomaterials, and paves the way for a novel and efficacious therapeutic avenue for the management of cardiovascular diseases.

Indexed as

Cardio-oncologyCardiotoxicityDiabetesDoxorubicinNrf2/HO-1 signaling pathwaySilicified curcuminVascular remodeling

Identifiers

PMID40144796
PMCPMC11937612

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.